It's obvious that the company has a good shot at returning to growth.One of the healthier stocks on the market Friday was veteran biotech Biogen (BIIB +8.82%). The company unveiled its final set of fundamentals for 2025, and it crushed analyst estimates for both trailing and forward profitability. It was little wonder that impressed market players piled into the stock, leaving it with a nearly 9% gain on the day.Fine despite the declinesBiogen's fourth quarter saw the company book total revenue of almost $2 ...

Core Viewpoint - Biogen's forecast for 2026 profits exceeds Wall Street's average expectations, indicating that significant cost-cutting measures are mitigating the impact of declining sales from its multiple sclerosis (MS) products [1][3]. Financial Performance - Biogen reported Q4 2025 total revenue of approximately $2.279 billion, a year-over-year decline of 7%, but still above Wall Street expectations. Adjusted earnings per share (EPS) were $1.99, also exceeding analyst forecasts [4]. - For the full year 2025, total revenue reached $9.891 billion, reflecting a 2% year-over-year increase, with adjusted EPS at $15.28, down 7% year-over-year, both surpassing Wall Street expectations [4]. - The company anticipates a mid-single-digit percentage decline in overall revenue for 2026, continuing the operational pressure on its MS treatment business [3][4]. Product Performance and Pipeline - The revenue from new drugs, particularly Leqembi, is crucial for Biogen's growth. In 2025, combined revenue from Leqembi, Skyclarys, Zurzuvae, and Qalsody approached $1 billion [4]. - Leqembi's sales in Q4 2025 were approximately $134 million, up from $121 million in the previous quarter, but growth is constrained by systemic bottlenecks in the healthcare system [5][7]. - Biogen is focusing on reducing reliance on neuroscience by enhancing its rare disease portfolio through acquisitions and shifting research emphasis towards immunology [6][9]. Strategic Initiatives - CEO Chris Viehbacher has implemented strict cost discipline, including job cuts and the removal of certain drugs from the development pipeline, to support new product growth [7]. - The company is seeking FDA approval for a subcutaneous administration of Leqembi, which could improve accessibility and differentiate it from competitors [9]. - Biogen is also awaiting key trial data for several experimental drugs, including a new Alzheimer's treatment and litifilimab for lupus, which could further diversify its product offerings [10].

Core Viewpoint - Biogen Inc. reported stronger-than-expected fourth-quarter 2025 results, leading to a more than 3% increase in shares, and provided an optimistic profit outlook for 2026 [1] Financial Performance - Adjusted earnings per share for Q4 2025 were $1.99, exceeding the analyst consensus of $1.61 [1] - Revenue for the quarter was $2.28 billion, surpassing expectations of $2.21 billion, although it represented a 7% decline year over year [1] Growth Products - Growth products showed positive momentum, with revenue increasing by 6% year over year in the quarter [2] - Global in-market sales of LEQEMBI reached approximately $134 million, marking a 54% year-over-year increase [2] - ZURZUVAE generated about $66 million in revenue, indicating strong demand growth [2] - SKYCLARYS expanded its global patient base by roughly 30% in 2025 [2] 2026 Outlook - For fiscal 2026, Biogen forecasts adjusted earnings per share in the range of $15.25 to $16.25, above the analyst consensus of $14.92 [3] - The company anticipates total revenue to decline by a mid-single-digit percentage compared to 2025, with expected declines in multiple sclerosis products, excluding VUMERITY, partially offset by growth in newer therapies [3]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Key Takeaways BIIB posted Q4 EPS of $1.99 and revenue of $2.28B, both beating estimates despite year-over-year declines.BIIB saw weakness in MS drugs and Spinraza, partly offset by growth from Leqembi, Skyclarys and Zurzuvae.BIIB guided 2026 adjusted EPS of $15.25-$16.25, above consensus, driving gains after the earnings release.Biogen (BIIB) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.99, which beat the Zacks Consensus Estimate of $1.61. Earnings declined 42% year over year.Total r ...

Biogen Leans Heavily Onto One Drug In Fourth-Quarter Beat | Investor's Business DailyBREAKING: [Dow Leads Stocks Higher As Nvidia, Goldman Sachs Rally]---Biogen (BIIB) narrowly topped Wall Street's fourth- quarter expectations Friday, thanks to far better-than-expected sales of multiple sclerosis treatment Tysabri. But Tysabri's victory lap could be short-lived. In November, Sandoz launched its generic version of the multiple sclerosis drug in the U.S. Biosimilars have existed in Europe for years and Tysabr ...

Biogen (NasdaqGS:BIIB) Q4 2025 Earnings call February 06, 2026 08:30 AM ET Company ParticipantsChristopher A. Viehbacher - President and CEOPriya Singhal - Head of DevelopmentRobin C. Kramer - EVP and CFOTim Power - Head of Investor RelationsUmer Raffat - Senior Managing DirectorOperatorGood morning, my name is Ruth and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen fourth quarter and full year 2025 earnings call and business update. All lines have bee ...

Biogen (NasdaqGS:BIIB) Q4 2025 Earnings call February 06, 2026 08:30 AM ET Company ParticipantsAlexandria Hammond - Director and Head of TherapeuticsBrian Abrahams - Managing Director and Co-Head of Biotechnology ResearchChris Schott - Managing DirectorChristopher A. Viehbacher - President and CEODanielle Brill - Managing DirectorEvan David Seigerman - Managing Director and Head of Healthcare ResearchMike Yee - Global Head of Biotechnology ResearchPriya Singhal - Head of DevelopmentRobin C. Kramer - EVP and ...

Biogen (NasdaqGS:BIIB) Q4 2025 Earnings call February 06, 2026 08:30 AM ET Speaker1Good morning, my name is Ruth and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen fourth quarter and full year 2025 earnings call and business update. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press star 1 on your ...

Core Insights - Biogen reported a financial loss due to a significant decline in revenue from its primary multiple sclerosis treatments, indicating challenges in its core business operations [1] Company Performance - The company experienced a double-digit percentage decline in revenue from its multiple sclerosis treatments, which are crucial to its financial health [1]